Literature DB >> 22944099

Risk factors for and prognosis of hemorrhagic cystitis after allogeneic stem cell transplantation: retrospective analysis in a single institution.

Yasuyuki Arai1, Takeshi Maeda, Hiroyuki Sugiura, Hiroyuki Matsui, Tomoyasu Jo, Tomoaki Ueda, Kazuya Okada, Takehito Kawata, Tatsuhito Onishi, Chisato Mizutani, Yasunori Ueda.   

Abstract

Hemorrhagic cystitis (HC) is a major complication after allogeneic stem cell transplantation (allo-SCT) and can be life threatening. To analyze risk factors and prognosis, we retrospectively reviewed 249 cases receiving allo-SCT in our institution. Median age was 47 years (13-72 years). Disease status at SCT was progressive in 73 cases. Conditioning was myeloablative (MAC) in 146 cases. Acute graft-versus-host disease (aGVHD) grade II-IV treated with prednisolone occurred in 82 cases, and cytomegalovirus (CMV) was reactivated in 91 cases. HC was reported in 47 cases at a median of 35 days (7-469 days) after SCT, and 34 (72.3%) cases recovered after a median of 19.5 days (2-252 days). In univariate analysis, the identified risk factors for HC included age over 45 years, progressive disease status, MAC, aGVHD treated with prednisolone, and CMV reactivation. In multivariate analysis, older age, MAC, and CMV remained independent predictors (hazard ratios: 2.35, 3.50, and 2.87). In patients with severe HC, percentage recovery was lower (3 in 13 cases; 23.1%) and the median duration was longer (54 days) than in those with moderate HC (31 in 36 cases; 86.1%, 17 days, P < 0.01). Treatment-related mortality was also higher (59.1%, P = 0.03) and overall survival was poorer (16.7%, P < 0.01) at 1 year after SCT. Prospective studies should be started considering prophylactic antiviral administration in high-risk patients such as those identified in this study.

Entities:  

Mesh:

Year:  2012        PMID: 22944099     DOI: 10.1179/1607845412Y.0000000010

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  9 in total

1.  Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival.

Authors:  L E Lunde; S Dasaraju; Q Cao; C S Cohn; M Reding; N Bejanyan; B Trottier; J Rogosheske; C Brunstein; E Warlick; J A H Young; D J Weisdorf; C Ustun
Journal:  Bone Marrow Transplant       Date:  2015-07-13       Impact factor: 5.483

Review 2.  The polyomavirus puzzle: is host immune response beneficial in controlling BK virus after adult hematopoietic cell transplantion?

Authors:  G Satyanarayana; F M Marty; C S Tan
Journal:  Transpl Infect Dis       Date:  2014-05-19       Impact factor: 2.228

3.  Effect of late-onset hemorrhagic cystitis on PFS after haplo-PBSCT.

Authors:  Hailong Yuan; Gang Chen; Jianhua Qu; Ruixue Yang; Maria Muhashi; Gulibadanmu Aizezi; Ming Jiang
Journal:  Open Med (Wars)       Date:  2021-10-05

4.  BKV Related Hemorrhagic Cystitis-An Insight into Risk Factors and Later Complications-An Analysis on Behalf of Polish Adult Leukemia Group.

Authors:  Jarosław Dybko; Agnieszka Piekarska; Siddarth Agrawal; Sebastian Makuch; Donata Urbaniak-Kujda; Monika Biernat; Blanka Rybka; Magdalena Dutka; Alicja Sadowska-Klasa; Sebastian Giebel; Lidia Gil
Journal:  Cancers (Basel)       Date:  2022-02-01       Impact factor: 6.639

5.  BK Polyomavirus Hemorrhagic Cystitis in Hematopoietic Cell Transplant Recipients.

Authors:  Sharon Anbumalar Lionel; Aby Abraham; Vikram Mathews; Kavitha Lakshmi; Asha Mary Abraham; Biju George
Journal:  J Glob Infect Dis       Date:  2022-02-28

6.  Prognostic Value of Thrombocytopenia in Myelodysplastic Syndromes After Hematopoietic Stem Cell Transplantation.

Authors:  Hong Wang; Jiaqian Qi; Xueqian Li; Tiantian Chu; Huiying Qiu; Chengcheng Fu; Xiaowen Tang; Changgeng Ruan; Depei Wu; Yue Han
Journal:  Front Oncol       Date:  2022-07-11       Impact factor: 5.738

7.  Incidence of late-onset hemorrhagic cystitis and its effect on PFS in acute leukemia patients after haplo-PBSCT: The 5-year single-center data.

Authors:  Hailong Yuan; Gang Chen; Jianli Xu; Ruixue Yang; Maria Muhashi; Gulibadanmu Aizezi; Ming Jiang
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738

8.  Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy.

Authors:  Yasuyuki Arai; Kazunari Aoki; June Takeda; Tadakazu Kondo; Tetsuya Eto; Shuichi Ota; Hisako Hashimoto; Takahiro Fukuda; Yukiyasu Ozawa; Yoshinobu Kanda; Chiaki Kato; Mineo Kurokawa; Koji Iwato; Makoto Onizuka; Tatsuo Ichinohe; Yoshiko Atsuta; Akiyoshi Takami
Journal:  J Hematol Oncol       Date:  2015-09-04       Impact factor: 17.388

9.  [Clinical analysis of hemorrhagic cystitis in children and adolescents with hematological diseases post haplo-hematopoietic stem cell transplantation].

Authors:  Y X Xie; Y Wang; X J Huang; L P Xu; X H Zhang; K Y Liu; C H Yan; F R Wang; Y Q Sun; J Kong; Y Q Gao; H Y Shi; D P Liu; Y F Cheng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-10-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.